857067-38-0 (2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol,2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y L]methyl]-6-methyl-pyridin-3-ol)

CAS号:
857067-38-0
中文名称:
2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol
英文名称:
2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y L]methyl]-6-methyl-pyridin-3-ol
分子式:
C22H29N5O3
分子量:
411.497364759445

2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol(857067-38-0)名称与标识符

名称

中文别名:
2-((6-(羟基甲基)-2-((3-吗啉丙基)氨基)-1H-苯并[d]咪唑-1-基)甲基)-6-甲基吡啶-3-醇;
英文别名:
2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol;2-((6-(HYDROXYMETHYL)-2-((3-MORPHOLINOPROPYL)AMINO)-1H-BENZO[D]IMIDAZOL-1-YL)METHYL)-6-METHYLPYRIDIN-3-OL;SCHEMBL8250779;DB-226356;857067-38-0;2-[[6-(hydroxymethyl)-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol;

标识符

InChIKey:
CUTGSBILRABNHA-UHFFFAOYSA-N
Inchi:
1S/C22H29N5O3/c1-16-3-6-21(29)19(24-16)14-27-20-13-17(15-28)4-5-18(20)25-22(27)23-7-2-8-26-9-11-30-12-10-26/h3-6,13,28-29H,2,7-12,14-15H2,1H3,(H,23,25)
SMILES:
O1CCN(CC1)CCCNC1=NC2C=CC(CO)=CC=2N1CC1C(=CC=C(C)N=1)O

2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol(857067-38-0)物化性质

计算特性

  • 精确分子量 : 411.22703980g/mol
  • 氢键供体数量 : 3
  • 氢键受体数量 : 8
  • 可旋转化学键数量 : 7
  • 同位素质量 : 411.22703980g/mol
  • 重原子数量 : 30
  • 复杂度 : 521
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 1.5
  • 拓扑分子极性表面积 : 95.7Ų

2-[[6-(hydroxymethyl)-2-(3-morpholinopropylamino)benzimidazol-1-y l]methyl]-6-methyl-pyridin-3-ol(857067-38-0)合成路线

合成路线:1 步
反应条件:
参考文献:
Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)
Bonfanti, Jean-Francois; et al, Journal of Medicinal Chemistry, 2008, 51(4), 875-896
合成路线:2 步
反应条件:
参考文献:
Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)
Bonfanti, Jean-Francois; et al, Journal of Medicinal Chemistry, 2008, 51(4), 875-896
合成路线:4 步
反应条件:
参考文献:
Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)
Bonfanti, Jean-Francois; et al, Journal of Medicinal Chemistry, 2008, 51(4), 875-896
合成路线:3 步
反应条件:
参考文献:
Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)
Bonfanti, Jean-Francois; et al, Journal of Medicinal Chemistry, 2008, 51(4), 875-896
合成路线:5 步
反应条件:
参考文献:
Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)
Bonfanti, Jean-Francois; et al, Journal of Medicinal Chemistry, 2008, 51(4), 875-896